{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:44:34Z","timestamp":1790145874653,"version":"4.0.1"},"reference-count":143,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic infections with either hepatitis B or C virus (HBV or HCV) are among the most common risk factors for developing hepatocellular carcinoma (HCC). The hepatocarcinogenic potential of these viruses is mediated through a wide range of mechanisms, including the induction of chronic inflammation and oxidative stress and the deregulation of cellular pathways by viral proteins. Over the last decade, effective anti-viral agents have made sustained viral suppression or cure a feasible treatment objective for most chronic HBV\/HCV patients. Given the tumorigenic potential of HBV\/HCV, it is no surprise that obtaining sustained viral suppression or eradication proves to be effective in preventing HCC. This review summarizes the mechanisms by which HCV and HBV exert their hepatocarcinogenic activity and describes in detail the efficacy of anti-HBV and anti-HCV therapies in terms of HCC prevention. Although these treatments significantly reduce the risk for HCC in patients with chronic viral hepatitis, this risk is not eliminated. Therefore, we evaluate potential strategies to improve these outcomes further and address some of the remaining controversies.<\/jats:p>","DOI":"10.3390\/cells10113091","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T12:46:23Z","timestamp":1636461983000},"page":"3091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-3526","authenticated-orcid":false,"given":"Saleh A.","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD 21287, USA"},{"name":"Liver Transplant Center, and Biostatistics, Epidemiology, and Scientific Computing Department, King Faisal Specialist Hospital & Research Center, Riyadh 11564, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"Liver Center, IRCCS San Raffaele Hospital, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref_1","unstructured":"(2020, December 03). WHO International Agency for Research on Cancer GLOBOCAN. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States from 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery","year":"2017","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"Plummer","year":"2015","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: A synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int."},{"key":"ref_8","unstructured":"WHO (2021, November 07). Global Hepatitis Report. Available online: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","article-title":"What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats","volume":"156","author":"Ward","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/j.1572-0241.2003.07678.x","article-title":"The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: Publication bias?","volume":"98","author":"Goodgame","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","article-title":"Annual Incidence of Hepatocellular Carcinoma Among Patients with Alcoholic Cirrhosis and Identification of Risk Groups","volume":"11","author":"Mancebo","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.30559","article-title":"Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study","volume":"123","author":"Mahale","year":"2017","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20160264","DOI":"10.1098\/rstb.2016.0264","article-title":"Human oncogenic viruses: Nature and discovery","volume":"372","author":"Chang","year":"2017","journal-title":"Philos. Trans. R. Soc. B: Biol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/j.gastro.2012.01.045","article-title":"Is Hepatitis C Virus Carcinogenic?","volume":"142","author":"Lemon","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jhep.2016.09.013","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection","volume":"66","author":"Chayanupatkul","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","article-title":"Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma","volume":"26","author":"Lau","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.4049\/jimmunol.181.9.6435","article-title":"Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire","volume":"181","author":"Rutebemberwa","year":"2008","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00535-008-2180-y","article-title":"Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies","volume":"43","author":"Li","year":"2008","journal-title":"J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s005350170027","article-title":"Hepatitis B virus X protein: A multifunctional viral regulator","volume":"36","author":"Murakami","year":"2001","journal-title":"J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.20245","article-title":"Hepatitis B virus X protein is essential for the activation of Wnt\/\u03b2-catenin signaling in hepatoma cells","volume":"39","author":"Cha","year":"2004","journal-title":"Hepatology"},{"key":"ref_24","first-page":"154","article-title":"Hepatocarcinogenesis in viral Hepatitis B infection: The role of HBx and p53","volume":"38","author":"Dewantoro","year":"2006","journal-title":"Acta Med. Indones."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1038\/emm.2016.177","article-title":"Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma","volume":"49","author":"Zhang","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., and Omata, M. (2019). Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061358"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s12072-016-9720-y","article-title":"Prevention of hepatitis B virus-associated liver diseases by antiviral therapy","volume":"10","author":"Tawada","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1038\/onc.2013.225","article-title":"Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial\u2013mesenchymal transition","volume":"33","author":"Quan","year":"2013","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1128\/MCB.00205-13","article-title":"Hepatitis B Virus X Protein-Induced Aberrant Epigenetic Modifications Contributing to Human Hepatocellular Carcinoma Pathogenesis","volume":"33","author":"Tian","year":"2013","journal-title":"Mol. Cell. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-09-2123","article-title":"Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes","volume":"16","author":"Braconi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.25849","article-title":"Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/cncr.22701","article-title":"Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis","volume":"109","author":"Pekow","year":"2007","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1096\/fj.01-0396com","article-title":"Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis","volume":"16","author":"Perlemuter","year":"2001","journal-title":"FASEB J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.27722","article-title":"Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma","volume":"61","author":"Yan","year":"2015","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2014.01.030","article-title":"Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression","volume":"25","author":"Lau","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0002-9440(10)63599-7","article-title":"Different Types of Ground Glass Hepatocytes in Chronic Hepatitis B Virus Infection Contain Specific Pre-S Mutants that May Induce Endoplasmic Reticulum Stress","volume":"163","author":"Wang","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/infdis\/jiu659","article-title":"Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System","volume":"211","author":"Liu","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: Clinical outcomes and durability","volume":"63","author":"Kim","year":"2013","journal-title":"Gut"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jvh.13283","article-title":"The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis","volume":"27","author":"Fonseca","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3748\/wjg.v23.i15.2651","article-title":"Hepatitis B virus infection and alcohol consumption","volume":"23","author":"Enomoto","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1055-9965.EPI-09-1297","article-title":"Interaction between Cigarette Smoking and Hepatitis B and C Virus Infection on the Risk of Liver Cancer: A Meta-analysis","volume":"19","author":"Chuang","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2013.09.029","article-title":"Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B","volume":"60","author":"Wong","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B","volume":"16","author":"Seto","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/CMAR.S188238","article-title":"Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: A meta-analysis and systematic review","volume":"11","author":"Tan","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/liv.12628","article-title":"Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment","volume":"35","author":"Kim","year":"2014","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/hep.24121","article-title":"Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)","volume":"53","author":"Jung","year":"2010","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3892\/etm.2016.3135","article-title":"Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B","volume":"11","author":"Huang","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.28115","article-title":"Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy","volume":"62","author":"Jung","year":"2015","journal-title":"Hepatology"},{"key":"ref_58","unstructured":"WHO (2021, November 07). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/246177."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhuang, L., Zeng, X.-T., Yang, Z., and Meng, Z. (2013). Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061361"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00535-009-0024-z","article-title":"Meta-analysis: The effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"44","author":"Miyake","year":"2009","journal-title":"J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2893.2009.01070.x","article-title":"Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: A meta-analysis","volume":"16","author":"Yang","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.27630","article-title":"Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan","volume":"61","author":"Chiang","year":"2014","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.31839","article-title":"Risk of HCC With Hepatitis B Viremia Among HIV\/HBV-Coinfected Persons in North America","volume":"74","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients with Low HBV Load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","article-title":"High Level of Hepatitis B Core\u2013Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load","volume":"157","author":"Tseng","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/djp180","article-title":"Associations between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis","volume":"101","author":"Liu","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jvh.13237","article-title":"A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance","volume":"27","author":"Ko","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ajg.2016.257","article-title":"Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study","volume":"111","author":"Ahn","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B","volume":"115","author":"Hsu","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No Difference in Incidence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir","volume":"18","author":"Oh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir Is Associated with Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2019","journal-title":"Gut"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis","volume":"73","author":"Dave","year":"2020","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: A systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.18632\/aging.202573","article-title":"No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: Evidence from an updated meta-analysis","volume":"13","author":"Yuan","year":"2021","journal-title":"Aging"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"284","DOI":"10.20517\/2394-5079.2017.38","article-title":"The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma","volume":"3","author":"Fung","year":"2017","journal-title":"Hepatoma Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2017","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tu, T., Budzinska, M.A., Shackel, N.A., and Urban, S. (2017). HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 9.","DOI":"10.3390\/v9040075"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1136\/gutjnl-2020-321309","article-title":"Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B","volume":"70","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study","volume":"3","author":"Gamkrelidze","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.30973","article-title":"Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B","volume":"71","author":"Goh","year":"2019","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins Are Associated with a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Jiang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.bjp.0704173","article-title":"Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)","volume":"133","author":"Eberlein","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2011.36.0917","article-title":"Statins and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection","volume":"30","author":"Tsan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2018.8342","article-title":"Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B","volume":"179","author":"Lee","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.47.5.610","article-title":"Interferon therapy reduces the risk for hepatocellular carcinoma","volume":"47","author":"Brown","year":"2000","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jhep.2016.08.001","article-title":"Management of the patient with SVR","volume":"65","author":"Terrault","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13013","article-title":"Is the benefit of treating patients with cirrhosis proven?","volume":"36","author":"Bruno","year":"2016","journal-title":"Liver Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/apt.14593","article-title":"Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: A retrospective cohort study","volume":"47","author":"Singer","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk","volume":"27","author":"Janjua","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14041","article-title":"Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma","volume":"39","author":"Mendizabal","year":"2019","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.3748\/wjg.v26.i43.6770","article-title":"Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end","volume":"26","author":"Muzica","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated with Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2019","journal-title":"Hepatology"},{"key":"ref_119","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study","volume":"19","author":"Tani","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/jmv.25984","article-title":"Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection","volume":"92","author":"Watanabe","year":"2020","journal-title":"J. Med Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/apt.14427","article-title":"Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis","volume":"47","author":"Mettke","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jvh.13261","article-title":"Long-term safety and efficacy results in hepatitis C virus genotype 1\u2012infected patients receiving ombitasvir\/paritaprevir\/ritonavir + dasabuvir \u00b1 ribavirin in the TOPAZ-I and TOPAZ-II trials","volume":"27","author":"Poordad","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","article-title":"Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis","volume":"73","author":"Sangiovanni","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41575-018-0018-5","article-title":"HCV therapy and risk of liver cancer recurrence: Who to treat?","volume":"15","author":"Colombo","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Lin, W.-C., Lin, Y.-S., Chang, C.-W., Chang, C.-W., Wang, T.-E., Wang, H.-Y., and Chen, M.-J. (2020). Impact of direct-acting antiviral therapy for hepatitis C\u2013related hepatocellular carcinoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233212"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-Acting Antiviral Therapy Not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Lui, F.H., Moosvi, Z., Patel, A., Hussain, S., Duong, A., Duong, J., and Nguyen, D.L. (2020). Decreased risk of hepatocellular carcinoma recurrence with directacting antivirals compared with no treatment for hepatitis C: A meta-analysis. Ann. Gastroenterol.","DOI":"10.20524\/aog.2020.0470"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Frazzoni, L., Sikandar, U., Metelli, F., Sadalla, S., Mazzella, G., Bazzoli, F., Fuccio, L., and Azzaroli, F. (2021). Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081694"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.13707","article-title":"Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression","volume":"38","author":"Aghemo","year":"2018","journal-title":"Liver Int."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Perez, S., Kaspi, A., Domovitz, T., Davidovich, A., Lavi-Itzkovitz, A., Meirson, T., Holmes, J.A., Dai, C.-Y., Huang, C.-F., and Chung, R.T. (2019). Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet., 15.","DOI":"10.1371\/journal.pgen.1008181"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e2985","DOI":"10.1097\/MD.0000000000002985","article-title":"Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy","volume":"95","author":"Seo","year":"2016","journal-title":"Medicine"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-2033-x","article-title":"Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: A prospective multicentre study","volume":"17","author":"Rinaldi","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated with Direct-Acting Antivirals for HCV Infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2019","journal-title":"Hepatology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","article-title":"aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis","volume":"73","author":"Fan","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.cgh.2018.12.018","article-title":"Cost Effectiveness of Hepatocellular Carcinoma Surveillance after a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis","volume":"17","author":"Zangneh","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","author":"Ioannou","year":"2020","journal-title":"J. Hepatol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/3091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:10Z","timestamp":1760167690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/11\/3091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":143,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cells10113091"],"URL":"https:\/\/doi.org\/10.3390\/cells10113091","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}